Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus - A meta-analysis

被引:109
作者
Norris, SL
Zhang, XP
Avenell, A
Gregg, E
Schmid, CH
Kim, C
Lau, J
机构
[1] CDCP, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA
[2] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB9 1FX, Scotland
[3] Tufts Univ, New England Med Ctr, Biostat Res Ctr, Boston, MA 02111 USA
[4] Tufts Univ, New England Med Ctr, Ctr clin Evidence Synth, Div Clin Care Res, Boston, MA 02111 USA
关键词
D O I
10.1001/archinte.164.13.1395
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Obesity is closely related to type 2 diabetes mellitus, and weight reduction is an important part of the care delivered to obese persons with diabetes. The objective of this review was to assess the efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes. Methods: A systematic review of the literature was performed, and studies were included if pharmacotherapy was used as the primary strategy for weight loss among adults with type 2 diabetes. Published and unpublished studies with any design were included. A random effects model was used to combine outcomes from randomized controlled trials. Results: Sufficient data for the meta-analysis were available for fluoxetine, orlistat, and sibutramine. Fourteen randomized, placebo-controlled trials were included in the review, with a total of 2231 patients. Pharmacotherapy produced modest reductions in weight for fluoxetine (3.4 kg [95% confidence interval (CI), 1.7-5.2 kg] at 8-16 weeks of follow-up; 5.1 kg [95% CI, 3.3-6.9 kg] at 24-30 weeks; and 5.8 kg [95% CI, 0.8-10.8 kg] at 52 weeks); orlistat (2.6 kg [95% CI, 2.1-3.2 kg] [2.6% loss] at 52 weeks); and sibutramine (4.5 kg [95% CI, 1.8-7.2 kg] [3.3% loss] at up to 26 weeks). Glycated hemoglobin was also modestly reduced: fluoxetine (1.0% [95% CI, 0.4%-1.5%] at 8-16 weeks; 1.0% [95% 0.6%-1.4%] at 24-30 weeks; and 1.8% [95% CI, -0.2%-3.8%] at 52 weeks); orlistat (0.4% [95% CI, 0.3%-0.5%]); and sibutramine (0.7% [95% CI, -0.5%-1.9%]). Gastrointestinal adverse effects were common with orlistat; tremor, somnolence, and sweating with fluoxetine; and palpitations with sibutramine. Conclusions: Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 26 to 52 weeks. However, the magnitude of weight loss was modest, and the long-term health benefits and safety remain unclear. Interventions that combine pharmacologic therapy with intensive behavioral interventions may be more effective but need additional research.
引用
收藏
页码:1395 / 1404
页数:10
相关论文
共 79 条
[1]  
Allison DB, 1996, INT J OBESITY, V20, P931
[2]   NUTRITION INTERVENTIONS FOR INTENSIVE THERAPY IN THE DIABETES CONTROL AND COMPLICATIONS TRIAL [J].
ANDERSON, EJ ;
RICHARDSON, M ;
CASTLE, G ;
CERCONE, S ;
DELAHANTY, L ;
LYON, R ;
MUELLER, D ;
SNETSELAAR, L .
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1993, 93 (07) :768-772
[3]   Obesity and disease management: Effects of weight loss on comorbid conditions [J].
Anderson, JW ;
Konz, EC .
OBESITY RESEARCH, 2001, 9 :326S-334S
[4]  
[Anonymous], 1998, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report
[5]  
[Anonymous], 2001, COCHRANE REV HDB
[6]  
[Anonymous], 1998, OB PREV MAN GLOB EP
[7]  
[Anonymous], 2000, Evidence-based diabetes care
[8]  
[Anonymous], [No title captured]
[9]   MEDICAL EVALUATION AND TREATMENT OF THE OBESE PATIENT WITH CARDIOVASCULAR-DISEASE [J].
BLACKBURN, GL ;
KANDERS, BS .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 60 (12) :G55-G58
[10]   Current and potential drugs for treatment of obesity [J].
Bray, GA ;
Greenway, FL .
ENDOCRINE REVIEWS, 1999, 20 (06) :805-875